A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Inclusion Criteria

• Histologically or cytologically confirmed RCC with clear cell component.
• Advanced/metastatic RCC or recurrent disease that has not previously been treated with systemic therapy in the 1L setting.
• Karnofsky Performance Status ≥ 70%.
• Provision of acceptable tumor sample.
• At least one lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and is suitable for accurate repeated measurements.

Exclusion Criteria

• History of leptomeningeal disease or spinal cord compression.
• Symptomatic brain metastases.
• Medical history of severe chronic obstructive pulmonary disease.
• Active or prior documented autoimmune or inflammatory disorders.
• Prior systemic therapy for advanced/metastatic RCC. Note - Other inclusion and exclusion criteria may apply as stated in the protocol.